Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + nivolumab
- Development stage
- Unknown
- Lead developer
- Elevar Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + nivolumab is an investigational combination therapy pairing **apatinib** (also known as rivoceranib), a small molecule anti-angiogenic agent inhibiting VEGFR2, with **nivolumab**, a monoclonal antibody checkpoint inhibitor targeting PD-1. Apatinib blocks blood vessel formation in tumors, while nivolumab releases inhibition on anti-tumor immune responses. Developed primarily for refractory, unresectable, or metastatic solid tumors, including advanced gastric cancer, this combination is being studied in early-phase trials for its safety, tolerability, and potential to improve clinical outcomes through synergy between targeted anti-angiogenesis and immunotherapy modalities[3][5][6][8].
- Other names
- rivoceranib + nivolumabapatinib + nivolumab combination
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on apatinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + nivolumab.